BACKGROUND: Sandoz adalimumab SDZ-ADL (GP-2017) is an approved adalimumab biosimilar with similar efficacy and comparable safety and immunogenicity to reference adalimumab (ref-ADL) as confirmed by analytical, pharmacokinetic and confirmatory studies. ADMYRA, a phase III double-blind study, was conducted with an aim to generate efficacy, safety and immunogenicity comparability data in patients with moderate-to-severe rheumatoid arthritis (RA) having inadequate response to disease-modifying anti-rheumatic drugs (DMARDs) including methotrexate (MTX). The study also evaluated an aspect of 'switching' reference product to the biosimilar in terms of efficacy, safety and immunogenicity up to Week 48. METHODS: Eligible patients (N = 353) were randomized 1:1 to receive subcutaneous (sc) SDZ-ADL 40 mg (n = 177) or ref-ADL (n = 176) every other week from Week 0 to Week 24. At Week 24, all patients with at least a moderate response by Disease Activity Score-28 including high-sensitivity C-reactive protein (DAS28-CRP) in the SDZ-ADL group continued SDZ-ADL (n = 159), and in the ref-ADL group were switched to SDZ-ADL (n = 166), treated for up to 46 weeks. The primary endpoint was change in DAS28-CRP from baseline at Week 12. Other efficacy endpoints included proportion of patients with European League Against Rheumatism (EULAR) response, EULAR remission, Boolean remission, safety and immunogenicity. RESULTS: The DAS28-CRP score changes from baseline at Week 12 were similar between SDZ-ADL (- 2.16) and ref-ADL (- 2.18) with a mean difference (95% CI) of 0.02 (- 0.24 to 0.27), which was within the pre-specified equivalence margin of ± 0.6. After switching treatment from ref-ADL to SDZ-ADL, the mean DAS28-CRP change was similar between the SDZ-ADL and 'ref-ADL/switched SDZ-ADL' group (- 3.09 vs - 3.05). The proportion of patients with good/moderate EULAR response was 69.2%/29.0% in the SDZ-ADL group and 68.0%/29.6% in the 'ref-ADL/switched SDZ-ADL' group. The proportion of patients in EULAR remission was 51.4% and 54.4% and in Boolean remission was 16.8% and 21.6% for SDZ-ADL and 'ref-ADL/switched SDZ-ADL' groups, respectively. The secondary endpoints were similar across the treatment groups. The incidence of adverse events (AEs) and injection-site reactions were low and similar between SDZ-ADL and 'ref-ADL/switched SDZ-ADL' groups (AEs 70.6% vs 68.8%, injection-site reactions 4.0% vs 6.3%), and most of these patients experienced AEs of mild or moderate severity. Antidrug antibodies were detected in 24.2% and 25.6% of patients treated with SDZ-ADL and 'ref-ADL/switched SDZ-ADL', respectively, from baseline to Week 48, of which 72.5% in SDZ-ADL and 79.1% in 'ref-ADL/switched SDZ-ADL' groups were neutralizing. CONCLUSIONS: In patients with moderate-to-severe RA who had an inadequate response to DMARDs, SDZ-ADL demonstrated a similar efficacy and a comparable safety and immunogenicity profile to ref-ADL. Efficacy was sustained after switching from ref-ADL to SDZ-ADL with no impact on safety (NCT02744755).

Arthritis and Rheumatic Disease Specialties Aventura FL USA

Department of Rheumatology and Connective Tissue Diseases University Hospital No 2 Collegium Medicum UMK Bydgoszcz Poland

Department of Rheumatology and Internal Medicine Medical University Wroclaw Poland

Global Clinical Development Biopharmaceuticals Hexal AG Holzkirchen Germany

Global Medical Affairs Biopharmaceutical Hexal AG Holzkirchen Germany

Hospital Central de la Defensa Glorieta Ejército 1 28047 Madrid Spain

MEDICAL PLUS s r o University of Veterinary and Pharmaceutical sciences Faculty of Pharmacy Uherske Hradiste Czech Republic

Rheumatology Private Practice Berlin Germany

RM Pharma Specialists Mexico City Mexico

Unidad de Reumatología Hospital Universitario de Fuenlabrada Fuenlabrada Madrid Spain

Zobrazit více v PubMed

Braun J, Kudrin A. Switching to biosimilar infliximab (CT-P13): evidence of clinical safety, effectiveness and impact on public health. Biologicals. 2016;44(4):257–266. doi: 10.1016/j.biologicals.2016.03.006. PubMed DOI

Smolen JS, Goncalves J, Quinn M, Benedetti F, Lee JY. Era of biosimilars in rheumatology: reshaping the healthcare environment. RMD Open. 2019;5(1):e000900. doi: 10.1136/rmdopen-2019-000900. PubMed DOI PMC

EuropeanMedicinesAgency. Biosimilars in the EU: Information guide for healthcare professionals. 2019. https://www.ema.europa.eu/en/documents/leaflet/biosimilars-eu-information-guide-healthcare-professionals_en.pdf. Accessed 07 May 2019.

EuropeanMedicinesAgency. Guideline on similar biological medicinal products containing monoclonal antibodies—non-clinical and clinical issues 2012. https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-similar-biological-medicinal-products-containing-monoclonal-antibodies-non-clinical_en.pdf. Accessed 07 May 2019.

FDA. Scientific Considerations in Demonstrating Biosimilarity to a Reference Product. 2015.

Kuek A, Hazleman BL, Ostor AJ. Immune-mediated inflammatory diseases (IMIDs) and biologic therapy: a medical revolution. Postgrad Med J. 2007;83(978):251–260. doi: 10.1136/pgmj.2006.052688. PubMed DOI PMC

EuropeanMedicinesAgency. Summary Of Product Characteristics. Hyrimoz. https://www.ema.europa.eu/en/documents/product-information/hyrimoz-epar-product-information_en.pdf. Accessed 07 May 2019.

FDA. Prescribing information. Hyrimoz. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/761071.pdf. Accessed 07 May 2019.

FDA. Highlights of prescribing information. Humira. https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/125057s0110lbl.pdf. Accessed 07 May 2019.

Markus R, Liu J, Ramchandani M, Landa D, Born T, Kaur P. Developing the totality of evidence for biosimilars: regulatory considerations and building confidence for the healthcare community. BioDrugs. 2017;31(3):175–187. doi: 10.1007/s40259-017-0218-5. PubMed DOI PMC

da Silva A, Fritsch C, Kronthaler U, Hofmann H-P, Hainzl O, Seidl A. Non-clinical pharmacological characterization and in-vivo efficacy of the proposed adalimumab biosimilar GP2017 compared to the originator adalimumab: 617. Am J Gastroenterol. 2016;111:S284. doi: 10.14309/00000434-201610001-00617. DOI

EuropeanMedicinesAgency. Summary of product characteristics. https://www.ema.europa.eu/en/documents/product-information/humira-epar-product-information_en.pdf. Accessed 07 May 2019.

Blauvelt A, Lacour JP, Fowler JF, Jr, Weinberg JM, Gospodinov D, Schuck E, et al. Phase III randomized study of the proposed adalimumab biosimilar GP2017 in psoriasis: impact of multiple switches. Br J Dermatol. 2018;179(3):623–631. doi: 10.1111/bjd.16890. PubMed DOI

Jauch-Lembach J, Skerjanec A, Haliduola H, Hass N, von Richter O, Fuhr R, et al. Randomized, double-blind, single-dose, three-arm parallel trial to determine the pharmacokinetics and safety of GP2017, EU- and US-adalimumab in healthy male subjects [abstract 2443]. Arthritis Rheumatol. 2017;69(S10).

Blauvelt A, Lacour J, Fowler J, Schuck E, Jauch-Lembach J, Balfour A, et al. Long-term efficacy, safety and immunogenicity results from a randomized, double-blind, phase III confirmatory efficacy and safety study comparing GP2017, a proposed biosimilar, with reference adalimumab [abstract 2440]. Arthritis Rheumatol. 2017;69(S10).

Fransen J, van Riel PL. The Disease Activity Score and the EULAR response criteria. Rheum Dis Clin North Am. 2009;35(4):745–57, vii–viii. PubMed

van Gestel AM, Prevoo ML, van ‘t Hof MA, van Rijswijk MH, van de Putte LB, van Riel PL. Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis. Comparison with the preliminary American College of Rheumatology and the World Health Organization/International League Against Rheumatism Criteria. Arthritis Rheum. 1996;39(1):34–40. PubMed

Hochberg MC, Chang RW, Dwosh I, Lindsey S, Pincus T, Wolfe F. The American College of Rheumatology 1991 revised criteria for the classification of global functional status in rheumatoid arthritis. Arthritis Rheum. 1992;35(5):498–502. doi: 10.1002/art.1780350502. PubMed DOI

Wiland P, Jeka S, Dokoupilova E, Limon JMM, Jauch-Lembach J, Thakur A, et al. Efficacy, safety, and immunogenicity results of the switch from reference adalimumab (ref-ADL) to sandoz biosimilar adalimumab (GP2017, SDZ-ADL) from ADMYRA phase 3 study in patients with moderate-to-severe rheumatoid arthritis (RA) Ann Rheum Dis. 2019;78:706–707.

Wiland P, Jeka S, Dokoupilová E, Miranda Limón JM, Jauch-Lembach J, Thakur A, et al. A randomized, double-blind, parallel-group, multicenter study to compare the efficacy, safety and immunogenicity of a proposed adalimumab biosimilar (GP2017) with reference adalimumab in patients with moderate-to-severe active rheumatoid arthritis [abstract 1936]. Arthritis Rheumatol. 2018;70(S10).

Schiestl M, Roesli C. Development and analytical characterization of GP2017: a proposed adalimumab biosimilar. Am J Gastroenterol. 2016;111:S289-S.

van Riel PL. The development of the disease activity score (DAS) and the disease activity score using 28 joint counts (DAS28). Clin Exp Rheumatol. 2014;32(5 Suppl 85):S-65-74. PubMed

van Riel PL, van Gestel AM. Area under the curve for the American College of Rheumatology improvement criteria: a valid addition to existing criteria in rheumatoid arthritis? Arthritis Rheum. 2001;44(7):1719–1721. doi: 10.1002/1529-0131(200107)44:7<1719::AID-ART300>3.0.CO;2-2. PubMed DOI

EuropeanMedicinesAgency. Guideline on clinical investigation of medicinal products for the treatment of rheumatoid arthritis. https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-clinical-investigation-medicinal-products-treatment-rheumatoid-arthritis_en.pdf. Accessed 07 May 2019.

Weinblatt ME, Keystone EC, Furst DE, Moreland LW, Weisman MH, Birbara CA, et al. Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum. 2003;48(1):35–45. doi: 10.1002/art.10697. PubMed DOI

Weise M, Bielsky MC, De Smet K, Ehmann F, Ekman N, Narayanan G, et al. Biosimilars-why terminology matters. Nat Biotechnol. 2011;29(8):690–693. doi: 10.1038/nbt.1936. PubMed DOI

EuropeanMedicinesAgency. Guideline on similar biological medicinal products. WC500180219. https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-similar-biological-medicinal-products-containing-biotechnology-derived-proteins-active_en-2.pdf. Accessed 07 May 2019.

Hemmington A, Dalbeth N, Jarrett P, Fraser AG, Broom R, Browett P, et al. Medical specialists’ attitudes to prescribing biosimilars. Pharmacoepidemiol Drug Saf. 2017;26(5):570–577. doi: 10.1002/pds.4186. PubMed DOI

Moots RJ, Xavier RM, Mok CC, Rahman MU, Tsai WC, Al-Maini MH, et al. The impact of anti-drug antibodies on drug concentrations and clinical outcomes in rheumatoid arthritis patients treated with adalimumab, etanercept, or infliximab: results from a multinational, real-world clinical practice, non-interventional study. PLoS One. 2017;12(4):e0175207. doi: 10.1371/journal.pone.0175207. PubMed DOI PMC

Petersen GL, Finnerup NB, Colloca L, Amanzio M, Price DD, Jensen TS, et al. The magnitude of nocebo effects in pain: a meta-analysis. Pain. 2014;155(8):1426–1434. doi: 10.1016/j.pain.2014.04.016. PubMed DOI PMC

Rezk MF, Pieper B. Treatment outcomes with biosimilars: be aware of the nocebo effect. Rheumatol Ther. 2017;4(2):209–218. doi: 10.1007/s40744-017-0085-z. PubMed DOI PMC

Cohen SB, Alten R, Kameda H, Hala T, Radominski SC, Rehman MI, et al. A randomized controlled trial comparing PF-06438179/GP1111 (an infliximab biosimilar) and infliximab reference product for treatment of moderate to severe active rheumatoid arthritis despite methotrexate therapy. Arthritis Res Ther. 2018;20(1):155. doi: 10.1186/s13075-018-1646-4. PubMed DOI PMC

Kay J, Schoels MM, Dorner T, Emery P, Kvien TK, Smolen JS, et al. Consensus-based recommendations for the use of biosimilars to treat rheumatological diseases. Ann Rheum Dis. 2018;77(2):165–174. doi: 10.1136/annrheumdis-2017-211937. PubMed DOI

Weinblatt ME, Baranauskaite A, Dokoupilova E, Zielinska A, Jaworski J, Racewicz A, et al. Switching from reference adalimumab to SB5 (adalimumab biosimilar) in patients with rheumatoid arthritis: fifty-two-week phase III randomized study results. Arthritis Rheumatol. 2018;70(6):832–840. doi: 10.1002/art.40444. PubMed DOI PMC

Gerdes S, Thaci D, Griffiths CEM, Arenberger P, Poetzl J, Wuerth G, et al. Multiple switches between GP2015, an etanercept biosimilar, with originator product do not impact efficacy, safety and immunogenicity in patients with chronic plaque-type psoriasis: 30-week results from the phase 3, confirmatory EGALITY study. J Eur Acad Dermatol Venereol. 2018;32(3):420–427. doi: 10.1111/jdv.14605. PubMed DOI PMC

Moots R, Azevedo V, Coindreau JL, Dorner T, Mahgoub E, Mysler E, et al. Switching between reference biologics and biosimilars for the treatment of rheumatology, gastroenterology, and dermatology inflammatory conditions: considerations for the clinician. Curr Rheumatol Rep. 2017;19(6):37. doi: 10.1007/s11926-017-0658-4. PubMed DOI PMC

Wiland P, Batko B, Brzosko M, Kucharz EJ, Samborski W, Swierkot J, et al. Biosimilar switching—current state of knowledge. Reumatologia. 2018;56(4):234–242. doi: 10.5114/reum.2018.77975. PubMed DOI PMC

Burmester GR, Panaccione R, Gordon KB, McIlraith MJ, Lacerda AP. Adalimumab: long-term safety in 23 458 patients from global clinical trials in rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis and Crohn’s disease. Ann Rheum Dis. 2013;72(4):517–524. doi: 10.1136/annrheumdis-2011-201244. PubMed DOI PMC

Sator P. Safety and tolerability of adalimumab for the treatment of psoriasis: a review summarizing 15 years of real-life experience. Ther Adv Chronic Dis. 2018;9(8):147–158. doi: 10.1177/2040622318772705. PubMed DOI PMC

Effect of treatment with original or biosimilar adalimumab on SARS-CoV2 vaccination antibody titers

Zobrazit více v PubMed

ClinicalTrials.gov
NCT02744755